Does IVF Increase Cancer Risk?
The answer from the best available long-term evidence is reassuring: IVF treatment does not meaningfully increase the risk of breast, ovarian, or uterine cancer for the general patient population.
Why Patients Ask This Question
IVF temporarily raises estrogen to 10-20 times normal levels during stimulation. This raises two concerns: (1) could high estrogen increase breast cancer risk? (2) could stimulating multiple eggs per cycle damage the ovarian surface epithelium?
These questions have been studied extensively for over two decades. Here is what the evidence shows.
Breast Cancer: Overall Reassuring
The Dutch OMEGA cohort study (van den Belt-Dusebout et al, JNCI 2016) -- 19,000+ women followed for a median of 21 years -- found no significant increase in breast cancer risk in IVF-treated women compared to subfertile controls.
A 2022 meta-analysis in Human Reproduction covering 1.8 million women found no statistically significant association between IVF gonadotropin stimulation and breast cancer.
ASRM 2023: Current evidence does not demonstrate a clinically meaningful increase in breast cancer risk from IVF.
| Study | Design | Finding |
|---|---|---|
| OMEGA cohort (Netherlands, 2016) | 19,158 women, 21-year follow-up | No significant breast cancer increase vs subfertile controls |
| Human Reproduction meta-analysis (2022) | 1.8 million women | No significant association with IVF gonadotropins |
| Nordic registry study | 200,000+ IVF patients | No endometrial cancer increase |
Ovarian Cancer: Complex But Reassuring for Invasive Disease
Infertility itself (particularly nulliparity) is an independent risk factor for ovarian cancer, which complicates studies. Key findings:
Invasive ovarian cancer: A large Swedish cohort study (Lundberg et al, 2019) found no significant increase in invasive ovarian cancer after IVF when controlling for infertility.
Borderline ovarian tumours (low malignant potential -- not invasive cancer): Some studies found a modestly elevated risk. The absolute risk is very low and borderline tumours have a very favourable prognosis.
ASRM 2023 and ESHRE 2022: Current evidence does not demonstrate a clinically meaningful increase in invasive ovarian cancer with IVF treatment.
Uterine and Cervical Cancer
No increased endometrial cancer risk found in large registry studies. No biological mechanism links IVF with cervical cancer (caused by HPV, not hormonal factors).
IVF-Conceived Children
Large registry studies covering hundreds of thousands of IVF-conceived children find no clinically meaningful increase in childhood cancer risk. ASRM 2023 considers the overall evidence on childhood health after IVF to be reassuring.
Who Needs Additional Monitoring
| Group | Recommendation |
|---|---|
| BRCA1 or BRCA2 carriers | Genetic counselling and oncology consultation before and after IVF |
| Women with PCOS | Baseline endometrial assessment if prolonged anovulation preceded IVF |
| Family history of ovarian cancer | Standard ovarian surveillance; discuss with oncologist |
| Prior breast cancer | Specialist oncofertility consultation required; modified letrozole protocols available |
For BRCA carriers: ASRM 2023 states that current data do not support withholding IVF, but genetic counselling and close oncology follow-up are recommended.
IVF After Breast Cancer
Per ESHRE Fertility Preservation Guideline 2020: modified stimulation protocols using letrozole with low-dose FSH minimise estrogen peaks during stimulation. Letrozole-based protocols are preferred for oestrogen receptor-positive cancers. Most oncologists recommend a waiting period (typically 2 years for low-risk disease) before attempting conception after breast cancer treatment.
Reference: ASRM Practice Committee -- IVF and Cancer Risk, 2023. ESHRE Fertility Preservation Guideline, 2020. van den Belt-Dusebout AW et al -- JNCI 2016. Human Reproduction meta-analysis, 2022. ACOG Committee Opinion No. 654, reviewed 2020.
Frequently Asked Questions
Does IVF cause cancer?▾
Current evidence does not show that IVF meaningfully increases cancer risk. The Dutch OMEGA cohort (19,000+ women, 21-year follow-up) found no significant breast cancer increase. ASRM 2023 states that IVF does not demonstrate a clinically meaningful increase in invasive ovarian or breast cancer risk. Women with BRCA mutations or prior cancer history should have specialist oncofertility consultation before starting IVF.
Is IVF safe for women with a family history of cancer?▾
For women with a family history of ovarian cancer, standard ovarian surveillance applies and an oncologist consultation is recommended. For BRCA1 or BRCA2 carriers, ASRM 2023 does not advise withholding IVF based on current evidence, but genetic counselling and close oncology follow-up are recommended. For women with a personal history of breast cancer, a specialist oncofertility consultation is essential before starting IVF.
Do fertility drugs increase cancer risk?▾
No clinically meaningful increase in invasive cancer has been demonstrated from fertility drugs (gonadotropins, letrozole, clomiphene) in large long-term studies. A modestly elevated risk of borderline ovarian tumours (not invasive cancer) has been seen in some studies, but the absolute risk is very low and prognosis is favourable. ASRM 2023 and ESHRE 2022 consider fertility drug use safe from an invasive cancer perspective for the general patient population.